Institutional members access full text with Ovid®

Share this article on:

The authors reply

Opal, Steven M. MD; Dellinger, R. Phillip MD, MCCM

doi: 10.1097/CCM.0000000000000059
Online Letters to the Editors

Infectious Disease Division, Memorial Hospital of Rhode Island, Providence, RI;

Cooper Health Systems, Camden, NJ; for the Surviving Sepsis Campaign Guidelines Committee

Dr. Opal served as board member for Arsanis, BioAegis, and Sciclone; consulted for Amplimmune; received royalties from Elsevier; and served on the data monitoring committee for Spectral, Achaogen, and Tetraphase. His institution received grant support from GlaxoSmithKline (preclinical research on genomics regulation), Asahi Kasei (Clinical coordinating center for clinical trial), and Cardeas (Clinical coordinating center for clinical trial). Dr. Dellinger disclosed that he does not have any potential conflicts of interest.

© 2013 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins